Short interest for Surmodics gives investors a sense of the degree to which investors are betting on the decline of Surmodics's stock. Short interest data is updated every two weeks.

Surmodics Stock (NASDAQ:SRDX), Short Interest Report

Surmodics

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ALGM

ASST

BFRG

BOOT

BRTX

CACC

CELU

CHRW

CMAX

CMND

CMPR

CTVA

DGII

EGHT

ELAB

ELWS

ETSY

EVAX

EVER

FBLG

FCEL

HSAI

IFBD

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MINM

NRBO

NVIV

NYCB

OGEN

PLUG

PSNY

PTON

RACE

REVB

RKLB

SPWR

SRDX

TCRT

VLCN

WOLF

YOSH

ZION

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ACLX

BABA

BFRI

CANO

CING

CJJD

CYCC

DFLI

DICE

DOYU

EBET

EDTX

EVLO

FFIE

FNGR

FRGE

FRTX

GOEV

GSX Techedu Inc. American Depositary Shares

GOTU

GRCL

HUYA

ICAD

INFI

LILM

LITE

LOCL

LYRA

Airspan Networks Holdings Inc. Common Stock

MIMO

MTLS

NKLA

NOAH

NUWE

NVAX

Nuveen California Dividend Advantage Municipal Fund 2

OLMA

QUOT

Lordstown Motors Corp. - Class A Common Stock

RIDE

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SEDG

SRGA

STRC

VALN

VCIG

XXII

ZJYL

Gainers


	Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.


Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

CVAC

VERA

U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.


DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday

Surmodics Inc

Guidance

Surmodics Sees FY24 Adj. EPS $(0.64)-$(0.47) Vs $(0.94) Est.; Revenue $122M-$124M Vs $119.644M Est.

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.32) by 121.88 percent. The company reported quarterly sales of $31.958 million which beat the analyst consensus estimate of $28.844 million by 10.80 percent. This is a 17.50 percent increase over sales of $27.198 million the same period last year.

Earnings

Earnings Beats

Surmodics Q2 2024 Adj EPS $0.07 Beats $(0.32) Estimate, Sales $31.958M Beat $28.844M Estimate

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Buy and maintains $47 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Surmodics, Maintains $47 Price Target

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrw#NASDAQ">CHRW</a>) fell sharply during Thursday&rsquo;s session after the company reported worse-than-expected fourth-quarter financial results.
C.H. Robinson Worldwide posted adjusted earnings of 50 cents per share, missing market estimates if 81 cents per share. The company&rsquo;s quarterly sales came in at $4.20 billion versus estimates of $4.34 billion.
C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares climbed 57.3% to $6.45. David E. Lazar recently disclosed a 51% active stake in Minim.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) jumped 51% to $2.17. Clearmind Medicine announced long-term licensing agreement with BIRAD.</li>
<li>NeuroBo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrbo#NASDAQ">NRBO</a>) climbed 52.9% to $5.00. NeuroBo Pharmaceuticals announced FDA clearance of IND for Phase 1 clinical trial of DA-1726 for the treatment of obesity.</li>
<li>FibroBiologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fblg#NASDAQ">FBLG</a>) shares climbed 47.4% to $42.90. FibroBiologics announced direct listing on the NASDAQ.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) rose 36% to $0.5191. Celularity said it sees FY24 net sales of $50 million to $56 million.</li>
<li>Cimpress plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmpr#NASDAQ">CMPR</a>) jumped 28.8% to $96.90 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares.</li>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) rose 28% to $0.2950.</li>
<li>Elevai Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elab#NASDAQ">ELAB</a>) gained 23.5% to $0.84 after gaining 8% on Wednesday.</li>
<li>Asset Entities Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asst#NASDAQ">ASST</a>) climbed 22.8% to $0.5650.</li>
<li>Kiora Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kprx#NASDAQ">KPRX</a>) shares jumped 20.4% to $0.6649. Kiora Pharmaceuticals announced a private placement of up to $45 million.</li>
<li>Evaxion Biotech A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evax#NASDAQ">EVAX</a>) gained 19.5% to $4.70. Evaxion Biotech announced pricing of $15 million public offering of 3.750 million ADS at $4.00 per ADS.</li>
<li>Nextracker Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxt#NASDAQ">NXT</a>) rose climbed 18.8% to $53.79 after the company reported better-than-expected third-quarter financial results.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) jumped 18.1% to $3.5791.</li>
<li>BioRestorative Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brtx#NASDAQ">BRTX</a>) gained 16.4% to $1.8850.</li>
<li>Corteva, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctva#NYSE">CTVA</a>) gained 16.2% to $52.84 after the company reported better-than-expected quarterly financial results, issued 2024 guidance and announced a $1 billion repurchase plan.</li>
<li>Nextracker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nxt#NYSE">NXT</a>) jumped 16.1% to $52.56 after the company reported better-than-expected quarterly financial results.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) rose 15.9% to $5.10.</li>
<li>FuelCell Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fcel#NASDAQ">FCEL</a>) gained 15.7% to $1.3885.</li>
<li>Plug Power Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plug#NASDAQ">PLUG</a>) climbed 12.2% to $4.9900. Plug Power said it completed first customer fill of liquid green hydrogen at its Georgia plant.</li>
<li>Credit Acceptance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cacc#NASDAQ">CACC</a>) jumped 11.9% to $605.43 following upbeat earnings.</li>
<li>Digi International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dgii#NASDAQ">DGII</a>) gained 11.7% to $27.17 following strong results.</li>
<li>Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) gained 11.1% to $2.5561 after dipping around 34% on Wednesday. Oragenics recently announced termination of at-market offering program.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/algm#NASDAQ">ALGM</a>) climbed 10.9% to $28.77 following upbeat earnings.</li>
<li>Ferrari N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/race#NYSE">RACE</a>) gained 10.4% to $382.17 after the company reported fourth-quarter financial results and issued 2024 guidance.</li>
<li>Etsy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) rose 9.6% to $72.95 after the company announced the appointment of Elliott Investment Management&rsquo;s Marc Steinberg to its board.</li>
<li>Boot Barn Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/boot#NYSE">BOOT</a>) gained 8.4% to $77.79 following upbeat earnings.</li>
<li>Sally Beauty Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbh#NYSE">SBH</a>) jumped 7.4% to $13.24 following upbeat earnings.</li>
<li>EverQuote, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ever#NASDAQ">EVER</a>) gained 7.2% to $13.53.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/db#NYSE">DB</a>) shares gained 6.2% to $13.65 after the company posted fourth-quarter results and announced plans to cut 3,500 jobs. Deutsche Bank plans to increase both share repurchases and dividends by at least 50% year-over-year in 2024.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/revb#NASDAQ">REVB</a>) shares dipped 61.1% to $3.4268 after the company announced pricing of $6.2 million public offering.</li>
<li>InVivo Therapeutics Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nviv#NASDAQ">NVIV</a>) fell 49% to $0.3267. InVivo Therapeutics Holdings and subsidiary filed for Chapter 11 bankruptcy in Delaware but plan to continue operating under court supervision as a debtor-in-possession.</li>
<li>Hesai Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsai#NASDAQ">HSAI</a>) declined 28.2% to $4.1817. Hesai Group issued a statement on the U.S. Department of Defense &quot;Chinese Military Companies&quot; list.</li>
<li>FibroBiologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fblg#NASDAQ">FBLG</a>) fell 27.4% to $21.12.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) shares dipped 24.3% to $0.1020 after the company announced a 1-for-45 reverse stock split.</li>
<li>Peloton Interactive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pton#NASDAQ">PTON</a>) fell 22.9% to $4.2850 after the company reported mixed second-quarter financial results and issued third-quarter revenue guidance below estimates.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) fell 21.4% to $8.10.</li>
<li>ADDvantage Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) shares declined 21.3% to $1.4320.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) fell 21.2% to $0.44 after surging more than 55% on Wednesday.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares declined 20.6% to $1.0799 after surging over 115% on Wednesday.</li>
<li>Alaunos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrt#NASDAQ">TCRT</a>) fell 19.3% to $2.0410.</li>
<li>Rocket Lab USA, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rklb#NASDAQ">RKLB</a>) shares declined 18.7% to $3.9450 after the company announced a proposed offering of $275 million convertible senior notes.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) fell 18.4% to $3.9736 after declining 9% on Wednesday. Bullfrog AI Holdings recently filed shelf offering of 786,938 shares and accompanying warrants at $6.63 per share and accompanying warrant.</li>
<li>Thermon Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/thr#NYSE">THR</a>) fell 16.2% to $27.45 following third-quarter results.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) declined 15.9% to $1.8250 after Volvo Cars said it will no longer provide further funding to the company.</li>
<li>Surmodics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srdx#NASDAQ">SRDX</a>) fell 14.9% to $29.97 following first-quarter results.</li>
<li>MaxLinear, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mxl#NYSE">MXL</a>) shares dipped 14.4% to $17.83 after reporting fourth-quarter results.</li>
<li>8x8, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eght#NASDAQ">EGHT</a>) fell 13.5% to $2.9050 following weak sales.</li>
<li>New York Community Bancorp, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NYSE">NYCB</a>) dipped 13.5% to $5.60 after multiple firms downgraded the stock following the company&#39;s fourth-quarter results.</li>
<li>IHS Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) fell 11.9% to $3.5050.</li>
<li>Western Alliance Bancorporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wal#NYSE">WAL</a>) dipped 10% to $57.58.</li>
<li>Aflac Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/afl#NYSE">AFL</a>) shares declined 9.7% to $76.17 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Markel Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkl#NYSE">MKL</a>) dipped 9.4% to $1,356.53 after the company reported 2023 financial results.</li>
<li>Wolfspeed, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wolf#NYSE">WOLF</a>) shares fell 9.2% to $29.56 following the company&#39;s second-quarter earnings.</li>
<li>Valley National Bancorp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vly#NASDAQ">VLY</a>) dipped 8% to $8.85.</li>
<li>Zions Bancorporation, National Association (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zion#NASDAQ">ZION</a>) fell 6.6% to $39.12.</li>
<li>ING Groep N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ing#NYSE">ING</a>) shares declined 5.9% to $13.37 following fourth-quarter results.</li>
<li>Sanofi (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sny#NASDAQ">SNY</a>) fell 3.2% to $48.33 after the company posted fourth-quarter results and named Fran&ccedil;ois-Xavier Roger as Chief Financial Officer.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/36889477/bitcoin-falls-following-jobless-claims-data-jupiter-ftx-token-among-top-losers"> Bitcoin Falls Following Jobless Claims Data; Jupiter, FTX Token Among Top Losers</a>

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Needham analyst Mike Matson maintains Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Buy and raises the price target from $44 to $47.

Needham Maintains Buy on Surmodics, Raises Price Target to $47

WIIM

Surmodics shares are trading lower after the company reported Q1 financial results and issued FY23 guidance.

Health Care

General

Surmodics Expects FY24 Adjusted EPS Loss Of $(1.17)-$(0.87) Compared To The Prior Guidance Of $(1.32)-$(0.97) And Consensus Of $(1.16)

Surmodics Expects FY24 Sales Of $117M-$121M, And $113M-$117M, Excluding SurVeil DCB License Fee Revenue, Compared To The Prior Guidance Of $116M-$121M, And $112M-$117M, Respectively, And The Consensus Of $119.26M

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.30) by 100.33 percent. This is a 100.2 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $30.55 million which beat the analyst consensus estimate of $29.64 million by 3.08 percent. This is a 22.54 percent increase over sales of $24.93 million the same period last year.

Surmodics Q1 Adjusted EPS $0.00 May Not Be Comparable To $(0.30) Estimate, Sales $30.55M Beat $29.64M Estimate

AAPL

AMZN

ATKR

BALL

BrightSphere Investment Group plc Ordinary Shares

BSIG

CLFD

COLM

COUR

CSWI

CVCO

DECK

ENSG

EVBN

EXPO

FCFS

FLWS

GOOS

HOLX

HUBG

Janus Henderson Group plc Ordinary Shares

KMPR

LANC

LESL

LPLA

MATW

MCHP

MIXT

MTSI

OCSL

ONEW

OTEX

PFSI

POST

RVTY

SHEL

SILC

SIRI

SKYW

TEAM

TECH

TSCO

VIAV

Earnings Scheduled For February 1, 2024

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-01. Here's what investors need to know before the announcement.
Analysts estimate that Surmodics will report an earnings per share (EPS) of $-0.30. 
Surmodics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.35, which was followed by a 5.93% drop in the share price the next day.
Here's a look at Surmodics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.18</td>
<td>0.05</td>
<td>-0.48</td>
<td>-0.66</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.53</td>
<td>0.52</td>
<td>-0.40</td>
<td>-0.50</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.93%</td>
<td>0.09%</td>
<td>-3.88%</td>
<td>3.31%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1706727698_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Surmodics were trading at $34.96 as of January 30. Over the last 52-week period, shares are up 23.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SRDX/earnings">To track all earnings releases for Surmodics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Surmodics's Earnings

The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently in limited market evaluation (LME), with full commercial launch planned following completion of the LME.

Surmodics Announced Early Clinical Use Of The Company's Pounce LP (Low Profile) Thrombectomy System

Surmodics Announced 24-month Data From The Swing Trial, A First-in-human Study Of The Safety And Performance Of Sundance Sirolimus Drug-Coated Balloon (DCB) At 50th annual VEITH Symposium In New York

Surmodics Announced The presentation Of 36-month Data From Its Transcend Clinical Trial By Dr. Peter A. Schneider At The 50th Annual Veith Symposium In New York, New York

Barrington Research analyst Michael Petusky maintains Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Outperform and raises the price target from $69 to $71.

Barrington Research Maintains Outperform on Surmodics, Raises Price Target to $71

Needham analyst Mike Matson maintains Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Buy and lowers the price target from $50 to $44.

Needham Maintains Buy on Surmodics, Lowers Price Target to $44

Surmodics Sees FY24 Non-GAAP Diluted Loss Per Share To Range From $(1.32)-$(0.97) Vs. $(1.24) Estimate

Surmodics Expects FY24 Total Revenue To Range From $116M-$121M Vs. $115.52M Estimate, Representing Decrease Of (13)%-(9)% Compared To FY23

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported adjusted quarterly earnings of $0.53 per share. This is a 303.85 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $27.97 million which beat the analyst consensus estimate of $26.27 million by 6.47 percent. This is a 7.63 percent increase over sales of $25.99 million the same period last year.

Surmodics Q4 Adj. EPS $0.53 Compared To $(0.26) In The Prior-Year Period, Sales $27.97M Beat $26.27M Estimate

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Surmodics Stock (NASDAQ:SRDX), Short Interest Report

People Also Watch